Akoya Ebit from 2010 to 2024

AKYA Stock  USD 3.22  0.05  1.58%   
Akoya Biosciences' EBIT is decreasing over the years with slightly volatile fluctuation. EBIT is expected to dwindle to about -58.8 M. From 2010 to 2024 Akoya Biosciences EBIT quarterly data regression line had arithmetic mean of (24,369,373) and significance of  0. View All Fundamentals
 
EBIT  
First Reported
2010-12-31
Previous Quarter
-56 M
Current Value
-58.8 M
Quarterly Volatility
19.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Akoya Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akoya Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 40.8 K, Depreciation And Amortization of 6 M or Interest Expense of 4.6 M, as well as many indicators such as Price To Sales Ratio of 2.13, Dividend Yield of 0.002 or PTB Ratio of 4.85. Akoya financial statements analysis is a perfect complement when working with Akoya Biosciences Valuation or Volatility modules.
  
Check out the analysis of Akoya Biosciences Correlation against competitors.
For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

Latest Akoya Biosciences' Ebit Growth Pattern

Below is the plot of the Ebit of Akoya Biosciences over the last few years. It is Akoya Biosciences' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akoya Biosciences' overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Slightly volatile
   Ebit   
       Timeline  

Akoya Ebit Regression Statistics

Arithmetic Mean(24,369,373)
Coefficient Of Variation(81.25)
Mean Deviation16,209,348
Median(13,504,000)
Standard Deviation19,800,473
Sample Variance392.1T
Range55M
R-Value(0.75)
Mean Square Error185.6T
R-Squared0.56
Significance0
Slope(3,314,269)
Total Sum of Squares5488.8T

Akoya Ebit History

2024-58.8 M
2023-56 M
2022-66.5 M
2021-37.7 M
2020-11.5 M

Other Fundumenentals of Akoya Biosciences

About Akoya Biosciences Financial Statements

Akoya Biosciences stakeholders use historical fundamental indicators, such as Akoya Biosciences' Ebit, to determine how well the company is positioned to perform in the future. Although Akoya Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Akoya Biosciences' assets and liabilities are reflected in the revenues and expenses on Akoya Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Akoya Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBIT-56 M-58.8 M
EBITDA-47.1 M-49.5 M
Ebt Per Ebit 1.13  1.30 
Ebit Per Revenue(0.58)(0.61)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:
Check out the analysis of Akoya Biosciences Correlation against competitors.
For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Revenue Per Share
1.889
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.18)
Return On Equity
(1.28)
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.